Fig. 4: Stratified genotype analysis of blood MCP-1 levels on categorized brain neuropathology using Fisher’s exact test in the FHS. | Translational Psychiatry

Fig. 4: Stratified genotype analysis of blood MCP-1 levels on categorized brain neuropathology using Fisher’s exact test in the FHS.

From: The impact of blood MCP-1 levels on Alzheimer’s disease with genetic variation at the NAV3 and UNC5C loci

Fig. 4

The FHS participants with neuropathology data (n = 78) were divided into NAV3\(-\) (rs696468 CC, n = 56) and NAV3\(+\) (rs696468 CT/TT, n = 22) genotype groups (A–D) or UNC5C\(-\) (rs72659964 AA, n = 73) and UNC5C\(+\) (rs72659964 AT/TT, n = 5) genotype groups (E–H). Due to the small sample size, brain neuropathology scores were divided into low- vs. high-score groups, including Braak stage (low = 0, 1, 2, 3 vs. high = 4, 5, 6) (A and E), CERAD (neocortical neuritic plaque, low = 0 vs. high = 1, 2, 3) (B and F), CERAD (diffuse plaques, low = 0,1 vs. high = 2, 3) (C and G) and microinfarcts (no vs. yes) (D and H). MCP-1 levels were also divided into low ( < 50%) and high ( ≥ 50%) groups. Bar charts showing the percentages of patients with categorized neuropathology scores within each MCP-1 group for each genotype of NAV3 and UNC5C. The number of participants, percentage, and Fisher exact test p values are shown.

Back to article page